News

Big Pharma supergroup dishes on de-personalizing clinical data

TransCelerate BioPharma, a nonprofit founded by some of the world's biggest drugmakers, is looking to standardize how the industry protects patient privacy when sharing data.

AMRI buys into proteomics to expand its discovery services

Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.

Catalent eyes another big year after a blockbuster IPO

Catalent dialed up its revenue and income in a busy fiscal 2014, and now the drug developer is projecting up to 5% sales growth in the coming year, counting on global expansion to extend its reach.

PPD looks to tamp down pesky placebos with new trial tech

Countless clinical trials are done in by unexpectedly well-performing placebo arms, a phenomenon particularly common in psychiatric studies. PPD believes a new, proprietary trial design can substantially level the playing field, and the CRO has paid an undisclosed sum to get its hands on the technology.

DPx buys its way into U.S. biologics with Gallus acquisition

DPx, the result of a $2.6 billion merger of Patheon and DSM Pharmaceutical Products, has acquired U.S. contract manufacturer Gallus BioPharmaceuticals.

Synexus snags another South African site and widens its footprint

Patient-recruitment specialist Synexus has expanded its presence in South Africa, buying up another trial site in the country as it touts a growing list of clients.

Cenix lands an early-phase deal with BASF's Metanomics

German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.

CRO Onyx signs up to help CRUK handle cancer R&D

Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.

PRA sets sights on a new PA hub

With months of dealmaking and mergers under its belt, CRO PRA Health Sciences is consolidating some of its outposts, constructing a new facility that will eventually house more than 850 employees.

Catalent lends its weight to an armed-antibody cancer candidate

Drug developer Catalent is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.

Recipharm buys into Italy with $165M CMO deal

Swedish contract developer Recipharm is looking to expand its share of the European manufacturing market, trading $164.5 million for Italy's Corvette Pharmaceutical Services.

Quintiles and Illumina look to jump-start cancer R&D with genomics sweepstakes

Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.

CRO PharPoint signs up to get Otologic's hearing drug into the clinic

Biotech Otologic Pharmaceuticals has chosen North Carolina's PharPoint Research to run an early trial of its lead candidate, a treatment for hearing loss.

Parexel: Biotech's boom pays dividends for CROs

Like most CROs, Parexel International relies on Big Pharma for most of its service revenue. But the recent explosion in biotech IPOs and venture capital deals has put a lot of money in the hands of small drugmakers, and that's changing the approach for the industry's largest contractors, a company exec said.

Evotec teams up with malaria nonprofit in open R&D project

German contract researcher Evotec has signed a deal with Medicines for Malaria Venture, lending its expertise to the nonprofit's efforts to encourage neglected disease R&D around the world.

Clinverse reels in a $9.1M funding round to expand its trial tech

Durham, NC's Clinverse has put together a $9.1 million C round, raising cash to support its technology for managing costs in clinical trials.

ABL teams up with Expression Therapeutics on a hemophilia treatment

Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A.

AMRI swings to revenue growth amid a transitional year

Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.

Evotec rides its risk-sharing model to revenue growth

German contract researcher Evotec posted 9% growth in the first half of 2014, executing on its plan to serve as both CRO and proprietary developer in a hybrid approach to R&D.

Shire bails out a contractor to keep its drug on the market

Repeated regulatory woes for SCM Pharma have left the U.K. contract manufacturer unable to afford its necessary upgrades, forcing Shire, its largest customer, to step in and take over.